Dr. Lu Hongzhou

President; Chief Physician; Professor (Grade II); Doctoral Supervisor

First clinician globally to identify and report a human H7N9 avian influenza case; led clinical rescue efforts during SARS, H1N1, and COVID-19 outbreaks; headed China's National Key R&D Programs on AIDS-tuberculosis co-infection across the 11th, 12th, and 13th Five-Year Plans; elected Fellow of the American Academy of Microbiology (2022); co-recipient of the French Gruber-Chaponack-Dubouchet Prize (2020) for COVID-19 origin research; completed postdoctoral training at the University of Pittsburgh

Dr. Lu leads Shenzhen's primary infectious disease hospital, which serves as a national clinical research center. International patients with HIV/AIDS, drug-resistant infections, or emerging infectious diseases can access care through the hospital's international services. Shenzhen is highly accessible from Hong Kong.

Research this doctor's background on trusted platforms.

Results are automated searches and may include other individuals with similar names.